LSKB Attending Bio Europe Spring in Stockholm
LSKB is attending Bio Europe Spring in Stockholm - schedule a meeting with us through the partnering system, or send us a message at alexkim@lskbiopharma.com
Author: ETadmin
LSK BioPharma and LSK Global PS Announce a Strategic Alliance for Global Clinical Trials
LSK BioPharma (LSKB), which is currently developing two promising cancer drugs, announced that it has entered into a strategic alliance with the largest CRO in Korea, LSK Global PS. The strategic alliance will initially focus on the clinical development of apatinib, a drug which has
LSK BioPharma and Huntsman Cancer Institute Announce an Exclusive License Agreement for HCI-1401, a BTK inhibitor for treatment of B-cell malignancies and other diseases
Salt Lake City– LSK BioPharma (LSKB) and the University of Utah’s Huntsman Cancer Institute (HCI) today announced an exclusive license agreement for LSKB to develop and commercialize HCI-1401, an orally bioavailable, small molecule, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). “BTK inhibitors are an exciting
LSK BioPharma at ASCO 2015
Dr. Sunil Sharma and Dr. Yoon Koo Kang in front of the Apatinib poster at ASCO 2015. Read The Abstract
LSKB announces initiation of a US clinical trial studying the dose escalation and safety of apatinib mesylate (YN968D1) in solid tumor cancers
Salt Lake City, UT, June 6, 2012 - LSK BioPartners today announced the initiation of a Phase 1/2A dose escalation and safety trial of apatinib mesylate (YN968D1) with the enrollment of the first three patients of the first dose cohort. This is the first clinical